Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.67 |
| ▸ | ECE1 | P42892 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.61 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.61 |
| ▸ | ITGAL | P20701 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30659508 | 0.93 | ACE (0.64) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL31253359 | 0.93 | ACE (0.64) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL1939435 | 0.92 | ACE (0.63) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL1939431 | 0.92 | ACE (0.63) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30659503 | 0.92 | ACE (0.63) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29405994 | 0.91 | KDM4E (0.65) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30310899 | 0.91 | ACE (0.67) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL3359705 | 0.91 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL9596897 | 0.91 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL5583839 | 0.91 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | AJK BIOPHARMACEUTICAL LLC (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | VIP, HM13, NGLY1 | ACE 2034/4885ECE1 3389/4885KDM4E 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.